Q-omics provides the consensus-scored C11orf86 profile across patient tissues and cancer cell-line models. C11orf86 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, C11orf86 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, C11orf86 RNA expression shows 11,109 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight UVM, COAD, and ESCA as cancer lineages where C11orf86 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C11orf86 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C11orf86 survival associations across molecular data types. C11orf86 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C11orf86 RNA expression–survival associations across cancer types. High C11orf86 expression shows unfavorable associations in UVM, KIRP, PAAD, THYM, LUAD and ACC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify UVM as the clearest survival context for C11orf86 RNA expression.
This table summarizes C11orf86 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for C11orf86. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C11orf86 shows lower tumor expression in COAD, READ, KICH and KIRP and higher tumor expression in LUAD and KIRC. The COAD box plot shows higher C11orf86 RNA expression in normal versus tumor tissue (log2 FC = −3.836, t-test p < 0.001).
This table shows molecular features associated with C11orf86 in patient tissues and cancer cell lines. In patient samples, C11orf86 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, C11orf86 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
